Report Description Table of Contents Latent Tuberculosis Infection Detection Market: Precision Screening Moves Prevention Upstream – (Updated On: 1st-Oct-2026) The Global Latent Tuberculosis Infection Detection Market was valued at USD 1.76 billion in 2025 and is projected to reach USD 2.58 billion by 2032, expanding at a CAGR of 5.58% during 2026–2032, according to Strategic Market Research. Latent Tuberculosis Infection Detection Market refers to the global market for diagnostic tests, laboratory platforms, and screening solutions used to identify individuals carrying Mycobacterium tuberculosis without active tuberculosis symptoms. The global burden of latent tuberculosis infection remains substantial, with an estimated 1.7 billion people globally living with latent tuberculosis infection (LTBI), creating a large unmet requirement for preventive screening and early identification programs. In the United States, an estimated 13 million people live with latent tuberculosis infection, with reactivation of untreated latent infection accounting for a significant proportion of active TB cases. The Centers for Disease Control and Prevention (CDC) estimates that around 80% of U.S. tuberculosis cases are associated with reactivation of untreated latent TB infection, reinforcing the need for systematic LTBI detection among high-risk populations. AP News According to the World Health Organization (WHO), 10.8 million people developed active tuberculosis globally in 2023, including 10.7 million adults and 1.25 million children, highlighting continued pressure on healthcare systems to identify individuals at risk before disease progression. The global TB burden remains concentrated in high-incidence regions, where expanded screening programs, preventive therapy initiatives, and improved diagnostic infrastructure are increasing demand for LTBI detection technologies. Wikipedia LTBI detection demand is increasingly influenced by public health strategies shifting from active disease management toward preventive intervention. Healthcare systems are expanding screening among people living with HIV (PLHIV), household contacts of TB patients, healthcare workers, migrants, immunosuppressed patients, and individuals receiving biological therapies. PLHIV remain a priority screening population because immune suppression significantly increases the probability of latent TB progression into active disease, creating sustained demand for reliable infection detection solutions. The diagnostic landscape is transitioning from conventional Tuberculin Skin Tests (TSTs) toward higher-specificity blood-based testing technologies. Tuberculin Skin Tests continue to represent a major testing method due to affordability, established public health usage, and suitability for large population screening programs. However, Interferon-Gamma Release Assays (IGRAs) are gaining adoption as healthcare providers increasingly prioritize improved specificity, reduced BCG vaccination interference, and single-visit testing workflows. Global LTBI testing volumes have reached tens of millions of tests annually, supported by occupational screening, immigration health assessments, TB contact investigations, and preventive healthcare programs. In developed healthcare markets, IGRA adoption is increasing across hospitals and reference laboratories, while cost-effective skin-based testing remains important in high-burden and resource-limited regions where large-scale screening programs require economical diagnostic approaches. Technological development is expanding beyond conventional immune-response detection toward precision-based infection risk assessment. Emerging approaches include recombinant antigen skin tests using ESAT-6 and CFP-10 proteins, advanced IGRAs measuring CD4/CD8 immune responses, host immune biomarkers, cytokine profiling, blood transcriptomic signatures, and proteomic-based diagnostic methods. These innovations aim to improve identification of recent infections, predict progression risk, and support targeted preventive treatment strategies. Laboratory automation is becoming a key commercial factor in LTBI diagnostics as healthcare networks seek higher testing capacity and workflow efficiency. Automated immunoassay platforms, digital laboratory systems, and integrated diagnostic solutions are gaining importance among centralized laboratories and hospital networks managing increasing screening volumes. Companies developing IGRA platforms and automated diagnostic workflows are focusing on improving testing accessibility, reducing manual processing requirements, and expanding adoption across regional healthcare systems. The competitive landscape is shaped by established diagnostic providers including QIAGEN, Revvity, Roche, bioMérieux, Abbott, Thermo Fisher Scientific, and regional diagnostic companies expanding TB screening capabilities. QIAGEN’s QuantiFERON-TB Gold Plus and Revvity’s T-SPOT.TB remain widely recognized IGRA platforms, while emerging automated and decentralized solutions are creating new opportunities for improving LTBI detection access. Overall, the Latent Tuberculosis Infection Detection Market is transitioning from conventional infection identification toward a precision screening ecosystem supported by targeted testing programs, preventive treatment expansion, laboratory automation, and increasing adoption of advanced blood-based diagnostic technologies. Growth opportunities are concentrated around IGRA adoption, decentralized screening platforms, biomarker-driven diagnostics, and healthcare initiatives focused on reducing progression from latent infection to active tuberculosis. Subsegment Leaders: Skin Tests Anchor Volume as Blood Assays Accelerate Leading Test Type (Technology): Tuberculin Skin Test (TST/Mantoux) — Largest Testing Volume Segment Tuberculin Skin Test (TST), also known as the Mantoux test, remains a widely used method for Latent Tuberculosis Infection (LTBI) detection by identifying immune sensitization to Mycobacterium tuberculosis through a delayed-type hypersensitivity response. The test involves intradermal administration of 0.1 mL purified protein derivative (PPD) tuberculin, followed by measurement of skin induration after 48–72 hours to determine infection status. With a ~62% market share in 2025 and USD 1.09 billion revenue contribution, TST continues to support LTBI screening programs across high-risk populations, healthcare workers, and TB control initiatives. Fastest-Growing Test Type (Technology): Interferon-Gamma Release Assays (IGRAs) — Transition Toward High-Specificity Blood Diagnostics Interferon-Gamma Release Assays (IGRAs) is gaining commercial importance as healthcare systems prioritize accurate identification of individuals carrying Mycobacterium tuberculosis without active disease symptoms. IGRAs evaluate T-cell immune responses against TB-specific antigens, including ESAT-6 and CFP-10, enabling more precise LTBI screening compared with traditional tuberculin skin testing. The segment accounted for approximately 34% market share in 2025, generating USD 0.60 billion in revenue, with growth projected at a 9.40% CAGR through 2032. IGRAs support TB prevention programs by improving detection among high-risk populations, including close contacts of TB patients, healthcare workers, and patients receiving immunosuppressive therapies. Their adoption is supported by advantages such as higher specificity due to BCG vaccine-independent antigen detection and single-visit blood testing, reducing follow-up requirements associated with tuberculin skin tests. Growth is further driven by increasing LTBI screening initiatives and global efforts to reduce progression from latent infection to active tuberculosis. Leading Application Segment: People Living with HIV (PLHIV) — Highest Clinical Priority Group People living with HIV (PLHIV) represent a major focus group within the Latent Tuberculosis Infection Detection Market due to their significantly elevated risk of TB reactivation caused by immune suppression. The risk of latent TB progressing to active disease increases by 10–110 times among PLHIV, making routine LTBI screening and preventive therapy a critical component of HIV care programs. The PLHIV-focused segment accounted for approximately 42% of the Latent Tuberculosis Infection Detection Market in 2025, generating USD 0.74 billion in revenue, and is projected to expand at a CAGR of 6.25% from 2026 to 2032. Growth is supported by WHO-recommended integration of latent and active TB screening at HIV diagnosis and care entry points. However, reduced immune response among patients with CD4 counts below 200 cells/µL can decrease the sensitivity of T-cell-based diagnostic methods, increasing the need for improved detection approaches and repeat screening protocols. Fastest-Growing Application Segment: Household & Close Contacts — Expansion Through Active Case Finding Household and close-contact screening remains a critical component of Latent Tuberculosis Infection Detection, accounting for nearly 28% market share in 2025 with revenue contribution of USD 0.49 billion. The segment is supported by rising implementation of TB contact investigation programs, where exposed individuals are systematically evaluated using Tuberculin Skin Tests (TSTs) and Interferon-Gamma Release Assays (IGRAs). Increasing focus on early LTBI identification among high-risk populations is expected to drive this segment at a 5.85% CAGR during 2026–2032. Leading Sample Type Segment: Blood-Based Testing — Laboratory Automation Advantage Blood-based testing is the leading approach in Latent Tuberculosis Infection Detection, with Interferon-Gamma Release Assays (IGRAs) such as QuantiFERON-TB Gold Plus and T-SPOT.TB accounting for nearly 63% market share in 2025, generating USD 1.11 billion in revenue. These assays identify latent Mycobacterium tuberculosis infection by measuring immune response activity, with adoption supported by single-visit testing convenience, reduced BCG vaccine interference, and increasing LTBI screening programs. The segment is projected to expand at a 7.25% CAGR from 2026 to 2032 as healthcare systems prioritize early TB identification and preventive treatment strategies. Fastest-Growing Technology Platform: Chemiluminescence & Automated Immunoassays — Next Laboratory Upgrade Cycle Chemiluminescence immunoassay (CLIA)-based platforms are becoming an important advancement in Latent Tuberculosis Infection (LTBI) Detection by improving the automation, analytical precision, and processing efficiency of Interferon-Gamma Release Assays (IGRAs). In 2025, CLIA-based LTBI detection solutions accounted for nearly 28% market share, generating USD 0.49 billion in revenue, with demand projected to expand at a 9.10% CAGR from 2026 to 2032. The adoption of automated CLIA analyzers is increasing in diagnostic laboratories due to faster IFN-γ measurement, reduced manual intervention, and improved testing capacity for tuberculosis screening programs. These systems quantify immune responses triggered by Mycobacterium tuberculosis-specific antigens, enabling reliable identification of latent infections, particularly in high-volume clinical and public health testing environments. Leading End User Segment: Diagnostic Laboratories — Core Revenue Generator Diagnostic laboratories represent the leading segment in the Latent Tuberculosis Infection Detection Market, accounting for approximately 55% market share in 2025 with revenue contribution of USD 0.97 billion. The segment is projected to expand at a CAGR of 6.85% during 2026–2032, driven by increasing adoption of Interferon-Gamma Release Assays (IGRAs), laboratory-based screening programs, and demand for accurate LTBI identification among high-risk populations. Laboratories primarily utilize IGRA-based blood tests, including QuantiFERON-TB Gold and T-SPOT.TB, to measure immune responses against Mycobacterium tuberculosis antigens, achieving high specificity while reducing false-positive outcomes associated with BCG vaccination. The growing need for tuberculosis elimination programs, healthcare worker screening, and immunocompromised patient testing continues to strengthen laboratory demand for LTBI detection solutions. Leading and Fastest-Growing Regional Segment: Asia-Pacific — Largest Latent TB Screening Opportunity Asia-Pacific Latent Tuberculosis Infection (LTBI) Detection market accounted for nearly 38% share in 2025, generating USD 0.67 billion in revenue, driven by expanding tuberculosis screening programs, rising adoption of interferon-gamma release assays (IGRAs), and government-led efforts for early identification of asymptomatic infections. With a projected CAGR of 7.25% during 2026–2032, LTBI detection is evolving from targeted clinical testing into a strategic component of regional TB elimination initiatives, supported by stronger surveillance networks and preventive treatment programs. The Next Diagnostic Wave: Antigens, Automation and Risk Signals New diagnostic approaches for latent tuberculosis infection (LTBI) are focused on improving detection accuracy, reducing false-positive results associated with BCG vaccination, simplifying testing workflows, and identifying individuals with a higher risk of progressing to active tuberculosis. While traditional tuberculin skin tests (TST) and established interferon-gamma release assays (IGRAs) remain the foundation of LTBI screening, emerging technologies are expanding beyond immune-response detection toward precision-based infection risk assessment. Recombinant Antigen Skin Tests (Next-Generation Skin Diagnostics) are emerging as an alternative to conventional PPD-based tuberculin testing. These tests use TB-specific antigens such as ESAT-6 and CFP-10, which are absent from BCG vaccine strains and most non-tuberculous mycobacteria. This approach improves specificity compared with traditional TST while maintaining the operational advantages of skin-based testing, making it suitable for large-scale screening programs in regions where laboratory infrastructure is limited. Advanced Interferon-Gamma Release Assays (IGRAs) represent the most commercially advanced innovation area in LTBI diagnostics. New-generation IGRA platforms are being developed with improved immune-cell stimulation methods, enhanced automation, and faster laboratory processing. Technologies such as QIAGEN QuantiFERON-TB Gold Plus and Revvity T-SPOT.TB measure TB-specific immune responses involving CD4+ and CD8+ T-cell activity, supporting more accurate detection among BCG-vaccinated individuals and high-risk populations. Chemiluminescence-Based and Automated IGRA Platforms are gaining attention as diagnostic laboratories move toward higher-throughput testing models. These platforms integrate automated sample handling, digital interpretation, and improved workflow efficiency, enabling large reference laboratories and hospitals to process increasing screening volumes. Adoption is particularly relevant in countries expanding migrant screening, occupational testing, and preventive TB programs. Host Immune Biomarker-Based Diagnostics represent a future-focused segment aiming to overcome a major limitation of current LTBI tests: the inability to determine which infected individuals are most likely to develop active TB. Research is evaluating immune markers including cytokine profiles, T-cell activation markers such as HLA-DR, and inflammatory signatures to distinguish stable latent infection from higher-risk disease progression. Blood Transcriptomics and Proteomics-Based Testing are emerging precision diagnostic approaches that analyze gene expression patterns, messenger RNA signatures, and protein biomarkers associated with TB progression. These technologies aim to identify recent infections and predict progression risk before clinical disease develops, supporting targeted preventive treatment strategies. Point-of-Care and Decentralized Diagnostic Platforms are also being developed to improve LTBI screening access in rural and high-burden regions. Microfluidic cartridges, portable immunoassays, and simplified testing platforms are designed to reduce dependence on centralized laboratories while supporting community-based TB elimination initiatives. Competitive Landscape: Assay Leaders Build Access Across Laboratory Networks QIAGEN N.V. — Global Leader in IGRA-Based LTBI Detection Key Product Portfolio: QuantiFERON-TB Gold Plus, QuantiFERON-TB Access QIAGEN is the leading company in the LTBI detection market through its QuantiFERON-TB Gold Plus (QFT-Plus) interferon-gamma release assay platform, which has become one of the most widely adopted blood-based diagnostics for latent TB screening. The company’s IGRA technology measures immune response against TB-specific antigens such as ESAT-6 and CFP-10, allowing detection of TB infection without interference from previous BCG vaccination. QIAGEN benefits from its established laboratory ecosystem, with QuantiFERON testing integrated into hospitals, reference laboratories, occupational screening programs, migrant health assessments, and TB control initiatives across multiple regions. The company has expanded its LTBI testing portfolio with QuantiFERON-TB Access, designed to improve accessibility in lower-resource settings by reducing laboratory complexity. The company’s commercial strength is supported by the increasing shift from traditional skin testing toward blood-based assays, particularly in North America and Europe, where healthcare systems prioritize higher-specificity diagnostics. QIAGEN operates globally across more than 25 countries and maintains a broad molecular diagnostics infrastructure supporting infectious disease testing. Revvity — Established Competitor Through T-SPOT.TB Technology Key Product Portfolio: T-SPOT.TB Interferon-Gamma Release Assay Revvity is one of the major players in LTBI diagnostics through its T-SPOT.TB assay, an ELISpot-based IGRA platform originally developed by Oxford Immunotec. The test detects TB infection by measuring the number of immune cells producing interferon-gamma after stimulation with TB-specific antigens, including ESAT-6 and CFP-10. T-SPOT.TB has gained adoption in hospitals, reference laboratories, and specialized screening programs due to its ability to provide reliable results in populations where traditional skin testing may be affected by BCG vaccination status. The platform is used in countries across North America, Europe, and Asia and is positioned as an alternative to QuantiFERON-based testing. Revvity has strengthened its diagnostic capabilities through automation initiatives, including integration of T-SPOT.TB processing with laboratory workflow solutions, enabling higher testing efficiency for centralized diagnostic networks. Other Important Companies and Their Market Roles F. Hoffmann-La Roche Ltd. – Expanding TB diagnostics through Elecsys IGRA TB testing on cobas laboratory systems, targeting automated high-throughput immunodiagnostic workflows. bioMérieux – Strengthening infectious disease diagnostics through immunoassay and decentralized testing technologies, supporting broader access to TB screening solutions. Abbott Laboratories – Supports infectious disease diagnostics through large global laboratory networks and automated testing platforms used in hospitals and reference laboratories. Thermo Fisher Scientific – Provides laboratory instruments, reagents, and automation technologies supporting infectious disease testing workflows and research applications. Beijing Wantai BioPharm – Supplies diagnostic products across Asia, supporting regional TB screening programs with cost-effective testing solutions. SD Biosensor – Develops rapid diagnostic platforms and infectious disease testing solutions, supporting decentralized healthcare settings in emerging markets. Eurobio Scientific – Provides specialized diagnostic products, including infectious disease testing solutions for European laboratory markets. Lupin Diagnostics – Expands TB diagnostic access in India through laboratory networks and infectious disease testing services. Hologic – Participates in molecular infectious disease diagnostics through advanced nucleic acid testing platforms, supporting broader TB diagnostic ecosystems. Analyst Outlook: Preventive Screening Moves Toward Precision The latent tuberculosis infection detection market is shifting from traditional skin-based screening toward a more advanced diagnostic ecosystem focused on high-specificity blood assays, automated laboratory platforms, and targeted preventive screening programs. The strongest growth opportunities are emerging around interferon-gamma release assays (IGRAs), decentralized testing solutions, improved TB risk stratification technologies, and biomarker-based approaches that can identify individuals with a higher probability of progressing from latent infection to active tuberculosis. Expanding TB elimination initiatives, rising screening among high-risk populations, and increasing adoption of precision diagnostics are reshaping the competitive landscape for global LTBI detection providers. Latent Tuberculosis Infection Detection Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.76 Billion Revenue Forecast in 2032 USD 2.58 Billion Overall Growth Rate CAGR of 5.58% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Test Type (Technology), By Application / Risk Group, By Sample Type, By Technology Platform, By End User, By Geography By Test Type (Technology) Tuberculin Skin Test (TST/Mantoux), Interferon-Gamma Release Assays (IGRAs), Emerging & Novel Diagnostic Tests By Application / Risk Group People Living with HIV (PLHIV), Household & Close Contacts, Other High-Risk Groups By Sample Type Blood-Based Testing, Skin-Based Testing By Technology Platform ELISA-Based IGRA Platforms, Chemiluminescence and Automated Immunoassay Platforms, Lateral Flow, Microfluidic, and Point-of-Care Platforms By End User Diagnostic Laboratories, Hospitals and Clinics, Academic & Public Health Institutions By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large global latent TB-infected population, expansion of risk-based screening programs, increasing adoption of interferon-gamma release assays, growing laboratory automation, rising TB prevention initiatives, and development of precision diagnostics for infection and progression-risk assessment Customization Option Available upon request Frequently Asked Question About This Report Q1: What factors are encouraging adoption across different sectors in the market? A1: Adoption is increasing as healthcare systems expand screening for people living with HIV, close contacts of TB patients, healthcare workers, migrants, and immunosuppressed individuals. Preventive TB programs are also creating steady demand for more accurate detection methods. Q2: How is technology advancement influencing adoption in the industry? A2: The shift toward blood-based IGRAs and automated immunoassay platforms is improving testing accuracy and laboratory efficiency. These technologies also reduce interference from BCG vaccination and support single-visit testing. Q3: What are the key trends shaping the market? A3: Major trends include growing use of IGRAs, laboratory automation, recombinant antigen skin tests, decentralized screening, and greater focus on identifying people at risk of progressing from latent infection to active tuberculosis. Q4: Which region is creating the strongest growth opportunity in the industry? A4: Asia-Pacific represents a major growth opportunity due to its high tuberculosis burden, expanding screening programs, stronger surveillance networks, and increasing adoption of advanced diagnostic technologies. The region is projected to grow at a 7.25% CAGR during 2026–2032. Q5: What emerging technologies could influence future market growth? A5: Host immune biomarkers, blood transcriptomics, proteomic signatures, microfluidic platforms, and automated IGRA systems could reshape future screening. These approaches aim to improve risk prediction and identify infections more precisely. Q6: What are the biggest challenges affecting industry expansion? A6: Key challenges include differences in healthcare access, the cost of advanced blood-based testing, limited laboratory infrastructure in some high-burden regions, and the inability of current tests to reliably predict which latent infections will progress to active disease. Sources: WHO – Global Tuberculosis Report 2024: Global TB Burden and 10.8 Million Cases WHO Global Tuberculosis Report 2024 WHO – Tuberculosis Preventive Treatment and Latent TB Infection Guidelines WHO TB Preventive Treatment Guidelines CDC – Latent Tuberculosis Infection: 13 Million U.S. Cases and Reactivation Risk CDC Latent TB Infection Overview CDC – TB Blood Tests / Interferon-Gamma Release Assays (IGRAs) CDC TB Blood Testing CDC – Tuberculin Skin Test (TST/Mantoux) Guidance CDC Tuberculin Skin Test Guidance QIAGEN – QuantiFERON-TB Gold Plus (QFT-Plus) QIAGEN QuantiFERON-TB Gold Plus Revvity – T-SPOT.TB Interferon-Gamma Release Assay Revvity T-SPOT.TB Roche Diagnostics – Elecsys IGRA TB Automated Testing Platform Roche Elecsys IGRA TB CDC – TB Testing: Blood Tests vs. Skin Tests and BCG Vaccination CDC Tuberculosis Testing WHO – LTBI Programmatic Management and High-Risk Population Screening WHO Latent TB Infection Guidelines Table of Contents - Global Latent Tuberculosis Infection Detection Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Investment Opportunities in the Latent Tuberculosis Infection Detection Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Interferon-Gamma Release Assays, Automated Immunoassay Platforms, Decentralized Testing, Biomarker-Based Diagnostics, Transcriptomic and Proteomic Testing, and Preventive TB Screening Programs Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Latent Tuberculosis Infection Detection in Preventive Screening, Risk-Based Testing, and TB Elimination Programs Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Diagnostic Accuracy, and Public Health Program Requirements Role of Risk-Based Screening, Interferon-Gamma Release Assays, Laboratory Automation, and Preventive Treatment Programs in Market Expansion Shift Toward High-Specificity Blood Diagnostics, Decentralized Testing, and Precision-Based TB Risk Assessment Global Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology): Tuberculin Skin Test (TST/Mantoux) Interferon-Gamma Release Assays (IGRAs) Emerging & Novel Diagnostic Tests Market Analysis by Application / Risk Group: People Living with HIV (PLHIV) Household & Close Contacts Other High-Risk Groups Market Analysis by Sample Type: Blood-Based Testing Skin-Based Testing Market Analysis by Technology Platform: ELISA-Based IGRA Platforms Chemiluminescence and Automated Immunoassay Platforms Lateral Flow, Microfluidic, and Point-of-Care Platforms Market Analysis by End User: Diagnostic Laboratories Hospitals and Clinics Academic & Public Health Institutions Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Country-Level Breakdown: United States Canada Mexico Europe Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Country-Level Breakdown: Brazil Argentina Mexico Rest of Latin America Middle East & Africa Latent Tuberculosis Infection Detection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User Country-Level Breakdown: GCC Countries Saudi Arabia UAE South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: QIAGEN N.V. Revvity, Inc. F. Hoffmann-La Roche Ltd. bioMérieux Abbott Laboratories Thermo Fisher Scientific Beijing Wantai BioPharm SD Biosensor Eurobio Scientific Lupin Diagnostics Hologic DiaSorin S.p.A. Fujirebio Molbio Diagnostics Danaher Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Assay Specificity, Laboratory Automation, Diagnostic Workflow Integration, Distribution Network, Public Health Program Participation, and Regional Presence Supplier Qualification and Compliance Capability Analysis Interferon-Gamma Release Assay Positioning Risk-Based Screening and Preventive TB Detection Competitiveness Automated Immunoassay, Decentralized Testing, and Laboratory Workflow Strategy Analysis DiaSorin S.p.A. Diagnostic technology provider with a focus on immunodiagnostics, automated laboratory workflows, infectious disease testing, and scalable diagnostic platforms relevant to TB screening ecosystems. Fujirebio Specialized diagnostics company with immunoassay capabilities and infectious disease testing expertise supporting laboratory-based screening and diagnostic applications. Molbio Diagnostics Indian molecular diagnostics company supporting decentralized tuberculosis testing and broader infectious disease screening through portable and point-of-care diagnostic solutions. Danaher Corporation Global diagnostics and life sciences company with laboratory automation, immunodiagnostic, molecular diagnostic, and decentralized testing capabilities supporting infectious disease diagnostic ecosystems. Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Diagnostic Providers Diagnostic Regulatory Compliance and Screening Program Risk Analysis Technology Adoption Trends Across Tuberculin Skin Test, Interferon-Gamma Release Assays, Automated Immunoassay Platforms, Lateral Flow, Microfluidic, and Point-of-Care Platforms List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Diagnostic Providers Market Share by Test Type (Technology), Application / Risk Group, Sample Type, Technology Platform, and End User (2025 vs. 2032) Global Latent Tuberculosis Infection Detection Ecosystem and Diagnostic Value Chain Analysis